New cancer Drug's interactions under the microscope
NCT ID NCT07388511
First seen Feb 05, 2026 · Last updated Jun 21, 2026 · Updated 23 times
Summary
This completed Phase 1 study looked at how a new drug called elenestinib affects the way the body processes midazolam (a sedative) and a common birth control pill. Twenty healthy adult women took these drugs with and without elenestinib, and researchers measured drug levels in their blood. The goal was to see if elenestinib changes how these other drugs work, which is important for future safe use.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANTS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Celerion, Inc
Tempe, Arizona, 85282, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
elenestinib
What this could lead to
If successful, this study will help doctors understand how elenestinib interacts with other drugs, leading to safer dosing guidelines.
What could go wrong
This is a very early, small study in healthy volunteers, not patients. Results may not predict effects in people with the disease or with other medications.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.